• Convulsive and pharmacological shock approaches defined early pharmacotherapy for schizophrenia and functional psychoses, systematizing metrazol/cardiazol regimens and insulin-assisted protocols with attention to convulsive responses and safety [7], [15], [14], [17], [13].

• A group of psychoactive drug studies examined stimulants' ability to elevate activity and mood in mental illness, while documenting boredom relief, improved engagement, and risk of acute hallucinatory states (amphetamines/benzedrine). [2], [3], [11].

• Biochemical and metabolic pharmacology centers on cerebral biochemistry amid insulin therapy and amino acid administration, linking metabolic shifts to behavioral change and cognitive/psychophysiological outcomes. [12], [4], [6].

• Neurophysiological and EEG-based assessments underpin pharmacological investigations, recording sedation effects, bromide/other drug influences on EEG, and therapeutic modalities such as electronarcosis. [10], [8], [20].

• Clinical outcome evaluations leverage psychometric and cognitive/behavioral assessments to interpret pharmacological treatments' impact on schizophrenia, including insulin-treated cases with Rorschach findings and related analyses. [5], [6].